Director Neal James R buys 789 shares (+2720.7%) as part of cluster pattern with 8 other insiders in 14 days
Neal James R, a director, purchased 789 shares at $2.54 on 2026-03-31, expanding his holdings from 29 shares to 818 shares (+2720.7% increase in position size). This transaction is part of a broader cluster pattern: 8 other insiders also bought within the past 14 days, suggesting coordinated or simultaneous conviction among the insider group. The company faces significant headwinds—it reported $0.00 revenue in the latest quarter, net income of $-3.4M over the most recent full fiscal year, and carries a $7.4M market cap, indicating an unprofitable pre-revenue or early-stage pharma operation. The stock is currently trading at $2.77, down -76.9% from its 52-week high of $11.97, though up 9.1% over the past 30 days. The cluster buy pattern warrants attention as a signal of potential management confidence, but the company's fundamental weakness (zero revenue, ongoing losses) and depressed valuation relative to recent highs should be weighed against insider accumulation.